Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Treating Lower Risk Myelofibrosis Patients
Expert Rev Hematol; 2017 Jan 10; Lancman, et al
Rationale for the use of JAK2 inhibitor therapy in lower risk myelofibrosis patients is beginning to emerge, according to a recent review.
The authors examined the use of ruxolitinib in such patients, including survival data from COMFORT-I and COMFORT-II. They also considered patient populations that may derive clinical benefit, and the future impact of molecular analysis on risk stratification and treatment.
They concluded that though use of ruxolitinib in low-risk patients needs to be validated in a randomized controlled trial, limited clinical data shows its potential for being used in the community setting eventually.
Lancman G, Mascarenhas J. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor? Expert Rev Hematol. 2017;10(1):23-28. doi:10.1080/17474086.2017.1264268.
